CL
Cell Source, Inc.
CLCS · OTC
$0.52 +4.00% (+$0.02)
1M -13.32%
Market Cap $30.6M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.71
36.5% upside
Current Price
$0.52
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CLCS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
-
N/A P/E N/A
EV/EBITDA N/A
P/FFO N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
Book val. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
FCF margin N/A
Quality
57 /100
Average ROIC 44.10%
ROA 1,665.17%
Asset turnover 0.00x
Debt
0 /100
High Current ratio 0.02x
Int. coverage -3.08x
Debt/Equity N/A
Stability
62 /100
Moderate Beta -157.98x
EPS volatility 3.67%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CLCS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Itamar Shimrat
Employees
1
Headquarters
New York City